Navigation Links
pHLIP, a novel technology to locate and treat tumors

Research teams at Yale University and the University of Rhode Island have demonstrated a new way to target and potentially treat tumors using a short piece of protein that acts like a nanosyringe to deliver “tags?or therapy to cells, according to a report in the Proceedings of the National Academy of Sciences.

The researchers show that, the protein fragment, called “pHLIP?(pH (Low) Insertion Peptide) can be injected into the abdomen of a mouse, find its way into the blood and then specifically accumulate in tumors. Within 20 hours after injection of labeled pHLIP, the molecules had passed through the bloodstream and accumulated in mouse breast tumors grown to different “stages?on the leg of a mouse.

The researchers demonstrated that by attaching fluorescent probes to a pHLIP peptide, tumors could be detected. They expect that by attaching and delivering active agents with pHLIP, that tumors may be able to be treated. Targeting is based on the fact that most tumors, even very small ones, are acidic as a result of the way they grow.

“Since the mechanism is general, and since even very small tumors can be targeted, there is an exciting array of possible applications for pHLIP,?said Donald Engelman, Eugene Higgins Professor of Molecular Biophysics & Biochemistry at Yale and a co-author of the paper.

“Andreev and Reshetnyak [co-authors of the paper] have taken a recent discovery from our lab and we are pushing hard as a team to test possible applications,?said Engelman. “We are very excited by the possibilities for both imaging and treating tumors.?

The pHLIP molecule has three states: soluble in water, bound to the surface of a membrane, and inserted across the membrane as an alpha-helix. Under normal tissue conditions of neutral pH, the water-soluble form is favored. At acidic pH, the transmembrane alp ha-helix predominates.

An earlier paper from the same groups shows that at low pH, pHLIP can move cell-impermeable molecules across a cell membrane, where they are released in the cytoplasm. “pHLIP acts as a molecular nanosyringe, inserting itself into the cell membrane and injecting compounds into cell,?said co-author Yana Reshetnyak, of the University of Rhode Island. “The transported molecules can be therapeutic or toxic to the cell, depending on the intended outcome—for treating cancer, the idea is to cause cell death.?

In addition to targeting tumors, other disease states that produce inflammation and cause tissue to be acidic are a target for pHLIP. “Acidosis is a physiological marker of many diseases ?and pHLIP feels acidity,?said Reshetnyak. “Therefore, pHLIP could also be used for monitoring of disease development and therapeutic outcomes. It might play very important role in the study of arthritis, ischemia and stroke.?

Lead author Oleg Andreev said, “We believe that universal medical tests to reveal many health problems at earlier stages may be developed based on pHLIP technology?

“Our discovery is an example of the reason that the NIH and DOD support basic science—we were working on the principles of membrane protein folding, and made a discovery with important medical implications that wouldn’t have happened without the ideas and approaches used in that work,?Engelman said.

Among the applications the team is actively pursuing are PET imaging of tumors, treatment of breast cancer, and alternative designs using the principles they have already established.
'"/>

Source:Yale University


Related biology news :

1. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
2. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
3. GeneNotes - A novel information management software for biologists
4. Endocannabinoids ?the brains cannabis ?demonstrate novel modes of action to stress
5. A novel virus for croup
6. Scientists show that tick-borne flaviviruses use a novel mechanism to evade host defenses
7. A novel method to measure circadian cycles
8. UCSD discovery may provide novel method to generate medically useful proteins
9. Updated data on novel HPV vaccine confirms efficacy in large population
10. Neurons generated in the adult brain learn to respond to novel stimuli
11. Federal grant funds research on novel HIV therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/20/2016)... 20, 2016 The rising popularity of ... leasing is stoking significant interest in keyless access ... Bluetooth low energy (BLE), biometrics and near-field communication ... wave of wireless technologies in the automotive industry. ... advanced access systems opens the market to specialist ...
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/16/2016)... DUBLIN , Dec 16, 2016 Research ... Access System Market - Global Forecast to 2021" report to ... ... projected to grow at a CAGR of 14.06% from 2016 to ... 2016, and is projected to reach 854.8 Million by 2021. The ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... 19, 2017 Research and Markets ... has announced the addition of the ... Forecast to 2025" report to their offering. ... The report provides a detailed analysis on current and future market trends ... using estimated market values as the base numbers Key ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 /PRNewswire/ ... a privately-held immunotherapeutics company targeting infectious diseases, announced ... the merger of PharmAthene and Altimmune in an ... Fund, HealthCap, Truffle Capital and Redmont Capital. The ... immunotherapeutics company with four clinical stage and one ...
(Date:1/19/2017)... , ... January 18, 2017 , ... ... Institutes of Health (NIH) to update its Data Sharing Policy. Specifically, the nation’s ... of grant applications subject to the existing policy. AMIA recommended that NIH earmark ...
(Date:1/19/2017)... ... 2017 , ... DaVita Clinical Research (DCR), a ... device development, and Prism Clinical Research , a leader in providing fully ... Clinical Trials (VCT) has been selected by both companies as an exclusive ...
Breaking Biology Technology: